Esperion Therapeutics, Inc. — Director's Dealing 2014

Oct 9, 2014

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Esperion Therapeutics, Inc. (ESPR)
CIK: 0001434868
Period of Report: 2014-10-07

Reporting Person: ENRIGHT PATRICK G (Director, 10% Owner)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2014-10-07	Common Stock	S	11692	$30.0402	Disposed	1884693	Indirect
2014-10-07	Common Stock	S	235	$30.0403	Disposed	37776	Indirect

Footnotes

F1: Reflects sales of Common Stock of the Issuer executed in multiple transactions at prices ranging from $30.00 to $30.30. The price reported reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the sales were effected.

F2: Reflects sales of Common Stock of the Issuer executed in multiple transactions at prices ranging from $30.00 to $30.30. The price reported reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the sales were effected.

F3: Mr. Enright is a managing member of Longitude Capital Partners, LLC ("Longitude Capital"). Longitude Capital, as general partner of each of Longitude Venture Partners, L.P. ("LVP") and Longitude Capital Associates, L.P. ("LCA"), has the power to vote and dispose of securities held by each of them and may be deemed to beneficially own the shares held by LVP and LCA. Mr. Enright disclaims beneficial ownership of the shares held by LVP and LCA, except to the extent of his pecuniary interest therein.